CVS Health (CVS)
NYSEHealth CareHealthcare PlansSnapshot 2026-07-08
$104.44+0.11%
Close 2026-07-08 · 1-day change
Reading CVS? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CVS free→NYSEHealth CareHealthcare PlansSnapshot 2026-07-08
Reading CVS? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CVS free→CVS grows revenue above $400 billion in 2026. Profit margin stays near 13.4%. Free cash flow rises to at least $9.5 billion. EPS guidance is raised to $7.30 per share.
Regulators may limit drug prices, hurting revenue and profits. CEO changes could disrupt plans. Growth could slow below 3% revenue increase.
The price is about 5% below our fair value near $109. Analysts expect 3% revenue growth, which we agree with.
Breaks if: Adjusted EPS guidance falls below $7.00 in FY26
CVS Health aims to increase its adjusted EPS guidance for the fiscal year 2026.
Stated in 3 of last 3 quarters. Adjusted EPS guidance increased from $7.00-$7.20 to $7.30-$7.50 for 2026. Revenue grew from $94.6B in 2025-Q1 to $100.4B in 2026-Q1. The trajectory is delivering on guidance increases.
Breaks if: Free cash flow falls below $9 billion in FY26
CVS Health is focused on increasing its cash flow from operations for the fiscal year 2026.
Stated in 3 of last 3 quarters. Cash flow from operations guidance increased to at least $9.5B for 2026. Cash from operations was $4.25B in 2026-Q1, up from $3.39B in 2025-Q4, indicating progress.
Breaks if: Operating margin falls below 12% in FY26
CVS Health aims to increase its adjusted EPS guidance for the fiscal year 2026.
Stated in 3 of last 3 quarters. Adjusted EPS guidance increased from $7.00-$7.20 to $7.30-$7.50 for 2026. Revenue grew from $94.6B in 2025-Q1 to $100.4B in 2026-Q1. The trajectory is delivering on guidance increases.
Breaks if: New drug price controls are enacted that limit revenue
Breaks if: Revenue falls below $400 billion in FY26
CVS Health aims to maintain its revenue guidance of at least $400 billion for the fiscal year 2026.
Stated in 2 of last 2 quarters. Revenue guidance for 2026 is at least $405B, up from $400B. Revenue grew from $94.6B in 2025-Q1 to $100.4B in 2026-Q1, showing positive trajectory.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Raising full-year 2026 guidance: Adjusted EPS guidance range to $7.30 to $7.50 from $7.00 to $7.20.”
“Confirmed Adjusted EPS guidance range of $7.00 to $7.20.”
“Raised Adjusted EPS guidance range to $6.55 to $6.65 from $6.30 to $6.40.”
“Raising full-year 2026 guidance: Cash flow from operations guidance to at least $9.5 billion from at least $9.0 billion.”
“Updated cash flow from operations guidance to at least $9.0 billion from at least $10.0 billion.”
“Updated cash flow from operations guidance to a range of $7.5 billion to $8.0 billion from at least $7.5 billion.”
“Raising full-year 2026 guidance: Adjusted EPS guidance range to $7.30 to $7.50 from $7.00 to $7.20.”
“Confirmed Adjusted EPS guidance range of $7.00 to $7.20.”
“Raised Adjusted EPS guidance range to $6.55 to $6.65 from $6.30 to $6.40.”
“Projected total revenues at least $405.0 billion.”
“The Company is initiating its 2026 full-year financial guidance: Total revenues of at least $400.0 billion.”